Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

March 24, 2016

Study Completion Date

June 16, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

Trial Locations (5)

Vienna

Marseille

Paris

Hanover

Milan